Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.49 |
| ▸ | AKT2 | P31751 | 15/20 | 0.49 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.49 |
| ▸ | FECH | P22830 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3623662 | 0.92 | AKT1 (0.47) | AKT1AKT2AKT3FECHKCNH2 | |
| SCHEMBL3619802 | 0.90 | AKT1 (0.43) | AKT1AKT2AKT3FECHKCNH2 | |
| SCHEMBL3622195 | 0.90 | AKT1 (0.49) | AKT1AKT2AKT3FECHKCNH2 | |
| SCHEMBL1674444 | 0.89 | AKT1 (0.51) | AKT1AKT2AKT3FECHKCNH2 | |
| SCHEMBL2283471 | 0.89 | AKT1 (0.58) | AKT1AKT2AKT3FECHKCNH2 | |
| SCHEMBL3625318 | 0.89 | AKT1 (0.47) | AKT1AKT2AKT3FECH | |
| SCHEMBL3620266 | 0.88 | AKT1 (0.46) | AKT1AKT2AKT3FECHKCNH2 | |
| SCHEMBL3621529 | 0.88 | AKT1 (0.51) | AKT1AKT2AKT3FECHKCNH2 | |
| SCHEMBL15899963 | 0.87 | AKT1 (0.50) | AKT1AKT2AKT3FECHKCNH2 | |
| SCHEMBL1674461 | 0.87 | AKT1 (0.49) | AKT1AKT2AKT3FECHKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022573-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2010-01-28 | — | — | US | claimed |
| EP-2303269-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8207169-B2 | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D | MSD K.K. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207169-B2 | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D | MSD K.K. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207169-B2 | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D | MSD K.K. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110092511-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-21 | — | — | US | disclosed |
| US-20110092511-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-21 | — | — | US | disclosed |
| US-20110092511-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-21 | — | — | US | disclosed |
| US-20100022573-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2010-01-28 | — | — | US | disclosed |
| US-20100022573-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2010-01-28 | — | — | US | disclosed |
| US-20100022573-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2010-01-28 | — | — | US | disclosed |
| WO-2009148916-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2008070134-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092511-A1 | INHIBITORS OF AKT ACTIVITY | AKT1S1, AKT1, PIK3CA | AKT1 2/4885AKT2 5/4885AKT3 8/4885 |
| US-20100022573-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3CG | AKT1 12/4885AKT2 4/4885AKT3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.